Impact of microbiome modulation on serum cytokine profile in a randomized, phase I trial of cabozantinib/nivolumab (cabo/nivo) with or without CBM588 in pts with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Li, Yu Jun [1 ]
Ebrahimi, Hedyeh [2 ]
Meza, Luis [2 ,3 ]
Malhotra, Jasnoor [2 ]
Li, Xiaochen [4 ]
Dizman, Nazli [2 ,5 ]
Dorff, Tanya [2 ]
Frankel, Paul [4 ]
Llamas-Quitiquit, Marian [2 ]
Hsu, JoAnn [2 ]
Zengin, Zeynep [2 ,3 ]
Alcantara, Marice [2 ]
Castro, Daniela [2 ]
Mercier, Benjamin [2 ]
Chawla, Neal [2 ]
Chehrazi-Raffle, Alexander [2 ]
Barragan-Carrillo, Regina [2 ]
Gillece, John [6 ]
Trent, Jeffrey [6 ]
Lee, Peter [7 ]
Parks, Thomas [8 ]
Takahashi, Motomichi [9 ]
Hayashi, Atsushi [9 ]
Caporaso, J. Gregory [10 ]
Lee, Keehoon [10 ]
Tripathi, Abhishek [2 ]
Pal, Sumanta [2 ]
机构：
[1] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA
[3] Yale Univ, Sch Med, New Haven, CT USA
[4] City Hope Comprehens Canc Ctr, Dept Biostat, Duarte, CA USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Translat Genom Res Inst TGen, Phoenix, AZ USA
[7] City Hope Comprehens Canc Ctr, Dept Immunooncol, Duarte, CA USA
[8] Osel Inc, Mountain View, CA USA
[9] Miyarisan Pharmaceut Co Ltd, Tokyo, Japan
[10] Translat Genom Res Inst TGen, Flagstaff, AZ USA
来源：
ONCOLOGIST | 2024年 / 29卷
关键词：
combination therapy; microbiome; probiotic;
D O I：
10.1093/oncolo/oyae181.059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
72
引用
收藏
页码：S36 / S37
页数：2
相关论文
共 50 条
  • [1] Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial.
    Ebrahimi, Hedyeh
    Meza, Luis A.
    Lee, Keehoon
    Malhotra, Jasnoor
    Alcantara, Marice
    Zengin, Zeynep Busra
    Dizman, Nazli
    Hsu, Joann
    Llamas-Quitiquit, Marian
    Castro, Daniela V.
    Mercier, Benjamin D.
    Barragan-Carrillo, Regina
    Chawla, Neal Shiv
    Li, Xiaochen
    Liu, Sandy
    Chehrazi-Raffle, Alex
    Dorff, Tanya B.
    Frankel, Paul Henry
    Tripathi, Abhishek
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 460 - 460
  • [2] Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.
    Ebrahim, Hedyeh
    Meza, Luis A.
    Dizman, Nazli
    Barragan-Carrillo, Regina
    Li, Xiaochen
    Llamas-Quitiquit, Marian
    Hsu, Joann
    Zengin, Zeynep Busra
    Castro, Daniela V.
    Mercier, Benjamin
    Zugman, Miguel
    Jaime-Casas, Salvador
    Chehrazi-Raffle, Alex
    Trent, Jeffrey M.
    Lee, Peter P.
    Takahashi, Motomichi
    Dorff, Tanya B.
    Caporaso, Gregory
    Lee, Keehoon
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 543 - 543
  • [3] Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial
    Ebrahimi, Hedyeh
    Meza, Luis A.
    Lee, Keehoon
    Malhotra, Jasnoor
    Alcantara, Marice
    Zengin, Zeynep Busra
    Dizman, Nazli
    Govindarajan, Ameish
    Hsu, Joann
    Llamas-Quitiquit, Marian
    Chawla, Neal Shiv
    Castro, Daniela V.
    Mercier, Benjamin D.
    Liu, Sandy
    Chehrazi-Raffle, Alex
    Dorff, Tanya B.
    Frankel, Paul Henry
    Li, Xiaochen
    Pal, Sumanta Kumar
    Tripathi, Abhishek
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA104 - LBA104
  • [4] Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.
    Ebrahimi, Hedyeh
    Meza, Luis A.
    Lee, Keehoon
    Malhotra, Jasnoor
    Alcantara, Marice
    Zengin, Zeynep Busra
    Dizman, Nazli
    Govindarajan, Ameish
    Hsu, Joann
    Llamas-Quitiquit, Marian
    Chawla, Neal Shiv
    Castro, Daniela V.
    Mercier, Benjamin D.
    Liu, Sandy
    Chehrazi-Raffle, Alex
    Dorff, Tanya B.
    Frankel, Paul Henry
    Li, Xiaochen
    Pal, Sumanta Kumar
    Tripathi, Abhishek
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [5] A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC)
    Meza, Luis A.
    Malhotra, Jasnoor
    Zengin, Zeynep Busra
    Dizman, Nazli
    Hsu, Joann
    Chawla, Neal Shiv
    Chehrazi-Raffle, Alex
    Muddasani, Ramya
    Govindarajan, Ameish
    Castro, Daniela V.
    Dorff, Tanya B.
    Lyou, Yung
    Frankel, Paul Henry
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A phase I trial to assess the biologic effect of CBM588 (Clostridium butyricum) in combination with nivolumab plus ipilimumab (nivo/ipi) in patients with metastatic renal cell carcinoma (mRCC)
    Bergerot, Paulo Gustavo
    Dizman, Nazli
    Ruel, Nora
    Frankel, Paul Henry
    Hsu, Joann
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC).
    Dizman, Nazli
    Pathak, Khyatiben
    Alcantara, Marice
    Meza, Luis A.
    Bergerot, Paulo Gustavo
    Willey, Maya
    Dorff, Tanya B.
    Hsu, Joann
    Zengin, Zeynep Busra
    Castro, Daniela V.
    Ebrahimi, Hedyeh
    Chehrazi-Raffle, Alex
    Tripathi, Abhishek
    Trent, Jeffrey M.
    Takahashi, Motomichi
    Oka, Kentaro
    Higashi, Seiya
    Kortylewski, Marcin
    Pirrotte, Patrick
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.
    Keeler, Molika Emmeline
    Kessler, Elizabeth Riley
    Bernard, Brandon
    Weisdack, Sarah
    Breaker, Kathryn M.
    Wold, Mali
    Ertz, Donna
    Weitzenkamp, David
    Flaig, Thomas W.
    Lam, Elaine Tat
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
    Barragan-Carrillo, R.
    Zengin, Z. B.
    Dizman, N.
    Ebrahimi, H.
    Meza, L. A.
    Jaime-Casas, S.
    Li, X.
    Dorff, T. B.
    Hsu, J.
    Salgia, N.
    Chehrazi-Raffle, A.
    Tripathi, A.
    Castro, D.
    Mercier, B.
    Caporaso, G.
    Lee, K.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1018 - S1018
  • [10] Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment.
    Dizman, Nazli
    Meza, Luis A.
    Bergerot, Paulo Gustavo
    Alcantara, Marice
    Dorff, Tanya B.
    Lyou, Yung
    Frankel, Paul Henry
    Llamas, Marian
    Hsu, Joann
    Zengin, Zeynep Busra
    Malhotra, Jasnoor
    Gillece, John D.
    Reining, Lauren J.
    Trent, Jeffrey M.
    Takahashi, Motomichi
    Oka, Kentaro
    Higashi, Seiya
    Highlander, Sarah K.
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345